Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Summary
A Phase N/A clinical trial (NCT07548476) has been registered on ClinicalTrials.gov evaluating combined acupuncture and virtual exercise (AVE) versus virtual exercise only (VE) for chemotherapy-induced peripheral neuropathy in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro). The study will assess feasibility and preliminary efficacy across two named intervention groups. Registered April 23, 2026.
“The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registration records a new clinical study (NCT07548476) investigating a combined acupuncture and virtual exercise intervention for managing chemotherapy-induced peripheral neuropathy in patients with metastatic bladder cancer receiving enfortumab vedotin and pembrolizumab. The trial establishes two study groups — Acupuncture + Virtual Exercise (AVE) and Virtual Exercise Only (VE) — and lists the study conditions as metastatic bladder cancer, peripheral neuropathy, advanced urothelial cancer, and metastatic urothelial cancer.
Affected parties include clinical investigators conducting oncology or supportive care research, healthcare providers treating CIPN in immunotherapy-treated bladder cancer patients, and patients enrolled in or considering the trial. The registration provides public notice of the study's existence, intervention arms, and eligibility conditions, enabling coordination with institutional review boards and recruitment efforts.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
N/A NCT07548476 Kind: NA Apr 23, 2026
Abstract
The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro).
The names of the two study groups in this research study are:
- Acupuncture + Virtual Exercise (AVE)
- Virtual Exercise Only (VE)
Conditions: Metastatic Bladder Cancer, Peripheral Neuropathy, Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Interventions: Acupuncture, Exercise
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.